Related Experiment Video
Updated: Aug 10, 2026
09:08
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Differential diagnosis between cutaneous lymphoma and pseudolymphoma
1Dermatopathology Section, Department of Dermatology, University of Graz, Auenbruggerplatz, 8, A-8036 Graz, Austria. lorenzo.cerroni@kfunigraz.ac.at
Analytical and Quantitative Cytology and Histology
|September 10, 2003
Summary
Diagnosing skin lymphoproliferative disorders is challenging. This article reviews criteria, including clinical, histopathologic, immunophenotypic, and molecular methods, to differentiate benign from malignant lymphoid infiltrates.
Area of Science:
- Dermatology
- Dermatopathology
- Immunohistochemistry
- Molecular Biology
Background:
- Differential diagnosis of cutaneous lymphoproliferative disorders (CLPDs) is a persistent challenge in dermatology and dermatopathology.
- Historically, diagnosis relied solely on clinicopathologic correlation.
- Recent advancements in immunohistochemical and molecular techniques offer new diagnostic criteria.
Purpose of the Study:
- To summarize the diagnostic criteria for differentiating benign from malignant lymphoid infiltrates in the skin.
- To provide a comprehensive overview of current approaches to CLPD diagnosis.
Main Methods:
- Review of clinicopathologic correlation.
- Integration of immunohistochemical techniques.
- Application of molecular diagnostic methods.
- Consideration of follow-up data in select cases.
Main Results:
- A synthesis of clinical, histopathologic, immunophenotypic, and molecular criteria is essential for accurate CLPD classification.
- No single method is sufficient; a multi-faceted approach is required.
- In some instances, longitudinal follow-up is necessary for definitive diagnosis.
Conclusions:
- Accurate classification of CLPDs necessitates a comprehensive approach integrating diverse diagnostic modalities.
- The combination of clinical, histopathological, immunophenotypic, and molecular data improves diagnostic precision.
- Follow-up data remains a critical component for resolving diagnostic uncertainties in CLPDs.
